Lowest Price Guaranteed
Pages
205
Last Updated
August 2026
View Count
13464
Chapter 2 is an executive summary of the insights captured in our research. It offers a high-level view on the current state of the market for immunocytokines and its likely evolution in the short-mid-term and long term.
Chapter 3 provides an introduction to immunocytokines, featuring brief descriptions of cytokines that are used for the treatment of oncological disorders. It also includes a discussion on the advent and evolution of engineered cytokines. The chapter lays emphasis on the advantages of engineered cytokines, including immunocytokines, and provides details on the strategies for the development of such therapies. It also features a brief discussion on the opportunities and the likely future trends in this field.
Chapter 4 provides information on over 75 immunocytokines that are currently under development for the treatment of rheumatoid arthritis and various cancer indications. It features a detailed analysis of pipeline molecules, based on phase of development (phase III, phase II / III, phase II, phase I / II, phase I, and discovery / preclinical stage) of lead candidates, type of therapy (monotherapy and combination therapy), type of cytokine used (IL, IFN, TGF-β, TNF, and others), type of antibody used (anti-CD20, anti-CEA, anti-CTLA-4, anti-DNA, anti-EDA, anti-EDB, anti-FAP, anti-GC2, anti-Her2, anti-KS, anti-PD-L1, anti-PD-1, anti-TA-MUC1, and anti-Tenascin-C), target disease indications (blood cancer, brain cancer, breast cancer, gastrointestinal cancer, gynecological cancer, head and neck cancer, lung cancer, prostate cancer, renal cancer, rheumatoid arthritis, skin cancer, undisclosed solid tumors, and others), and route of administration (intravenous, intratumoral, subcutaneous, and others). In addition, the chapter includes details of the companies developing these immunocytokines, including information on year of establishment, company size, and location of headquarters.
Chapter 5 provides tabulated profiles of the companies that are engaged in the development of more than three immunocytokines. Each profile features a brief overview of the company, its financial information (if available), product portfolio, recent developments and an informed future outlook.
Chapter 6 provides an insightful analysis of recent developments in this domain. It features list of partnerships that have been inked by stakeholders in this domain, during the period between January 2016 and October 2020, and a brief description of partnership models (such as clinical trial agreements, licensing agreements, mergers and acquisitions, research agreements, research and development agreements, and others). In addition, the report features an analysis of the investments made at various stages of development in companies focused on developing immunocytokines.
Chapter 7 provides a detailed analysis of completed, ongoing, and planned clinical studies of various immunocytokines, highlighting prevalent trends across various relevant parameters, such as trial registration year, phase of development, current trial status, enrolled patient population, study design, leading industry players (in terms of number of trials conducted), study focus, target therapeutic area, and key geographical regions.
Chapter 8 provides an analysis of KOLs in the field of immunocytokines. It features a comprehensive list of principal investigators of different clinical trials, along with information on the affiliated research institutes. The chapter features a schematic world map representation, highlighting the geographical locations of eminent scientists / researchers who are engaged in clinical research in this domain. It also presents a comparative analysis, highlighting those KOLs who have relatively more experience in this domain. The (relative) level of expertise of different KOLs defined by other analysts / industry experts were compared to the results obtained using a proprietary scoring criteria, which was based on parameters, such as number of publications, number of citations, participation in clinical trials, number of affiliations, and strength of professional network (based on information available on LinkedIn).
Chapter 9 features an insightful market forecast analysis, highlighting the likely growth of immunocytokines market, till the year 2030. In order to provide details on the future opportunity, our projections have been segmented on the basis of [A] target disease indications (cervical cancer, cholangiocarcinoma, esophageal cancer, gallbladder cancer, head and neck cancer, melanoma, non-small cell lung cancer, rheumatoid arthritis, and soft tissue sarcoma), [B] routes of administration (intravenous, intratumoral, and subcutaneous), and [C] key geographical regions (US, Canada, Germany, UK, France, Italy, Spain, China, Japan, South Korea, Australia, Brazil, Argentina, Israel, and Turkey). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.
Chapter 10 is a collection of interview transcripts of discussions held with key stakeholders in this market. In this chapter, we have presented a brief overview of the companies and details of our conversations held with Stephen Gillies (President and CEO, Provenance Biopharmaceuticals) and Patrik Kehler (Senior Director Scientific and Business Development, Glycotope).
Chapter 11 summarizes the entire report. It presents the key takeaways and offers our independent opinion on the current market scenario. Further, it captures the evolutionary trends that are likely to determine the future of the immunocytokines market.
Chapter 12 is an appendix, which provides tabulated data and numbers for all the figures included in the report.
Chapter 13 is an appendix, which contains a list of companies and organizations mentioned in this report.
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Overview of Cytokines
3.2.1. Engineered Cytokines and Immunocytokines
3.3. Challenges Associated with the Development of Immunocytokines
3.4. Future Perspectives
4. CURRENT MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Immunocytokines: Development Pipeline
4.2.1. Analysis by Phase of Development
4.2.2. Analysis by Type of Therapy
4.2.3. Analysis by Type of Cytokine Used
4.2.4. Analysis by Type of Antibody Used
4.2.5. Analysis by Target Disease Indication(s)
4.2.6. Analysis by Route of Administration
4.2.7. Analysis by Phase of Development, Type of Therapy, and Type of Cytokine Used
4.3. Immunocytokines: List of Therapy Developers
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size and Geographical Location
4.3.3. Leading Developers: Analysis by Number of Therapies
4.3.4. Regional Analysis of Therapy Developers
5. COMPANY PROFILES
5.1. Chapter Overview
5.2. Genopharm
5.2.1. Company Overview
5.2.2. Immunocytokines Portfolio
5.2.2.1. GNP101
5.2.2.2. GNP201
5.2.2.3. GNP301
5.2.3. Recent Developments and Future Outlook
5.3. ImmunGene
5.3.1. Company Overview
5.3.2. Immunocytokines Portfolio
5.3.2.1. IGN001
5.3.2.2. IGN003
5.3.2.3. IGN004
5.3.2.4. IGN005
5.3.2.5. IGN006
5.3.3. Recent Developments and Future Outlook
5.4. Kanaph Therapeutics
5.4.1. Company Overview
5.4.2. Immunocytokines Portfolio
5.4.2.1. KNP-101
5.4.2.2. KNP-102
5.4.2.3. Cytokine X-Anti-Target A
5.4.2.4. Cytokine X-Anti-Target B
5.4.3. Recent Developments and Future Outlook
5.5. Merck KGaA
5.5.1. Company Overview
5.5.2. Immunocytokines Portfolio
5.5.2.1. EMD 521873
5.5.2.2. M7824
5.5.2.3. M9241
5.5.3. Recent Developments and Future Outlook
5.6. Philogen
5.6.1. Company Overview
5.6.2. Immunocytokines Portfolio
5.6.2.1. Daromun
5.6.2.2. F8IL10
5.6.2.3. F16IL2
5.6.2.4. IL12-L19L19
5.6.2.5. L19IL2
5.6.2.6. L19TNF
5.6.3. Recent Developments and Future Outlook
6. RECENT DEVELOPMENTS
6.1. Chapter Overview
6.2. Recent Developments: Partnerships and Collaborations
6.3. List of Partnerships and Collaborations
6.3.1. Analysis by Year of Partnership
6.3.2. Analysis by Type of Partnership
6.3.3. Analysis by Year of Partnership and Type of Partner
6.3.4. Most Active Players: Analysis by Number of Partnerships
6.3.5. Regional Analysis
6.3.5.1. Intercontinental and Intracontinental Agreements
6.4. Recent Developments: Types of Funding
6.5. Funding and Investment Analysis
6.5.1. Analysis by Number of Funding Instances (Cumulative), 2016-2020
6.5.2. Analysis by Amount Invested
6.5.3. Analysis by Type of Funding
6.5.4. Most Active Players: Analysis by Number of Funding Instances and Amount Invested
6.5.5. Investment Summary by Region
7. CLINICAL TRIAL ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. Immunocytokines: Clinical Trial Analysis
7.3.1. Analysis by Trial Registration Year
7.3.2. Analysis by Trial Phase
7.3.3. Analysis by Trial Recruitment Status
7.3.4. Analysis by Trial Registration Year and Number of Patients Enrolled
7.3.5. Analysis by Study Design
7.3.6. Analysis by Sponsor / Collaborator
7.3.7. Most Active Players: Analysis by Number of Registered Trials
7.3.8. Emerging Focus Areas
7.3.9. Analysis by Trial Phase and Target Disease Indication
7.3.10. Geographical Analysis by Number of Clinical Trials
7.3.11. Geographical Analysis by Number of Patients Enrolled
8. KEY OPINION LEADERS (KOL) ANALYSIS
8.1. Chapter Overview
8.2. Assumptions and Methodology
8.3. Principal Investigators Involved in Clinical Trials
8.3.1. Analysis by Type of Organization (KOL Affiliation)
8.3.2. Geographical Distribution of KOLs
8.4. Prominent KOLs
8.5. KOL Benchmarking: Roots Analysis’ Assessment versus Third Party (ResearchGate Score)
8.6. Most Active KOLs
8.6.1. KOL Profile: A (Maastricht University)
8.6.2. KOL Profile: B (Centre Léon Bérard)
8.6.3. KOL Profile: C (Eberhard Karls University)
8.6.4. KOL Profile: D (Istituto Clinico Humanitas)
8.6.5. KOL Profile: E (Washington University in St. Louis)
9. MARKET FORECAST AND OPPORTUNITY ANALYSIS
9.1. Chapter Overview
9.2. Forecast Methodology and Key Assumptions
9.3. Global Immunocytokines Market, 2021-2030
9.4. Global Immunocytokines Market, 2021 and 2030: Distribution by Target Disease Indication
9.4.1. Immunocytokines Market for Cervical Cancer, 2021-2030
9.4.2. Immunocytokines Market for Cholangiocarcinoma, 2021-2030
9.4.3. Immunocytokines Market for Esophageal Cancer, 2021-2030
9.4.4. Immunocytokines Market for Gallbladder Cancer, 2021-2030
9.4.5. Immunocytokines Market for Head and Neck Cancer, 2021-2030
9.4.6. Immunocytokines Market for Melanoma, 2021-2030
9.4.7. Immunocytokines Market for Non-small Cell Lung Cancer, 2021-2030
9.4.8. Immunocytokines Market for Rheumatoid Arthritis, 2021-2030
9.4.9. Immunocytokines Market for Soft Tissue Sarcoma, 2021-2030
9.5. Global Immunocytokines Market, 2021 and 2030: Distribution by Route of Administration
9.5.1. Immunocytokines Market for Products Requiring Intravenous Administration, 2021-2030
9.5.2. Immunocytokines Market for Products Requiring Intratumoral Administration, 2021-2030
9.5.3. Immunocytokines Market for Products Requiring Subcutaneous Administration, 2021-2030
9.6. Global Immunocytokines Market, 2021 and 2030: Distribution by Geography
9.6.1. Immunocytokines Market in the US, 2021-2030
9.6.2. Immunocytokines Market in Canada, 2021-2030
9.6.3. Immunocytokines Market in Germany, 2021-2030
9.6.4. Immunocytokines Market in the UK, 2021-2030
9.6.5. Immunocytokines Market in France, 2021-2030
9.6.6. Immunocytokines Market in Italy, 2021-2030
9.6.7. Immunocytokines Market in Spain, 2021-2030
9.6.8. Immunocytokines Market in China, 2021-2030
9.6.9. Immunocytokines Market in Japan, 2021-2030
9.6.10. Immunocytokines Market in South Korea, 2021-2030
9.6.11. Immunocytokines Market in Australia, 2021-2030
9.6.12. Immunocytokines Market in Brazil, 2021-2030
9.6.13. Immunocytokines Market in Argentina, 2021-2030
9.6.14. Immunocytokines Market in Turkey, 2021-2030
9.6.15. Immunocytokines Market in Israel, 2021-2030
9.7. Immunocytokines Market, 2021-2030: Product-wise Sales Forecasts
9.7.1. Daromun
9.7.1.1. Target Patient Population
9.7.1.2. Sales Forecast
9.7.2. F8IL10
9.7.2.1. Target Patient Population
9.7.2.2. Sales Forecast
9.7.3. hu14.18-IL2
9.7.3.1. Target Patient Population
9.7.3.2. Sales Forecast
9.7.4. L19IL2
9.7.4.1. Target Patient Population
9.7.4.2. Sales Forecast
9.7.5. L19TNF
9.7.5.1. Target Patient Population
9.7.5.2. Sales Forecast
9.7.6. M7824
9.7.6.1. Target Patient Population
9.7.6.2. Sales Forecast
9.7.7. RO6874281
9.7.7.1. Target Patient Population
9.7.7.2. Sales Forecast
10. EXECUTIVE INSIGHTS
10.1. Chapter Overview
10.2. Provenance Biopharmaceuticals
10.2.1. Company Snapshot
10.2.2. Interview Transcript: Stephen Gillies, President and Chief Executive Officer
10.3. Glycotope
10.3.1. Company Snapshot
10.3.2. Interview Transcript: Patrik Kehler, Senior Director Scientific and Business Development
11. CONCLUDING REMARKS
12. APPENDIX 1: TABULATED DATA
13. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
Figure 3.1 Strategies for the Development of Engineered Cytokines
Figure 4.1 Immunocytokines: Distribution by Phase of Development
Figure 4.2 Immunocytokines: Distribution by Type of Therapy
Figure 4.3 Immunocytokines: Distribution by Type of Cytokine Used
Figure 4.4 Immunocytokines: Distribution by Type of Antibody Used
Figure 4.5 Immunocytokines: Distribution by Target Disease Indication(s)
Figure 4.6 Immunocytokines: Distribution by Phase of Development and Target Disease Indication(s)
Figure 4.7 Immunocytokines: Distribution by Route of Administration
Figure 4.8 Funnel Analysis: Distribution by Phase of Development, Type of Therapy, and Type of Cytokine Used
Figure 4.9 Immunocytokines: Distribution of Developers by Year of Establishment
Figure 4.10 Immunocytokines: Distribution of Developers by Company Size and Geographical Location
Figure 4.11 Leading Developers: Distribution by Number of Therapies
Figure 4.12 World Map Representation: Distribution by Regional Activity
Figure 6.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2016-2020 (Till October)
Figure 6.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 6.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 6.4 Partnerships and Collaborations: Distribution by Year and Type of Partner
Figure 6.5 Most Active Players: Distribution by Number of Partnerships
Figure 6.6 Partnerships and Collaborations: Regional Distribution
Figure 6.7 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 6.8 Funding and Investments: Cumulative Year-wise Trend, 2016-2020 (Till October)
Figure 6.9 Funding and Investments: Distribution of Amount Invested by Year and Number of Instances, 2016-2020 (USD Million)
Figure 6.10 Funding and Investments: Distribution of Instances by Type of Funding
Figure 6.11 Funding and Investments: Distribution by Year and Type of Funding, 2016-2020 (Till October)
Figure 6.12 Funding and Investments: Distribution of Instances by Total Amount Invested and Type of Funding (USD Million)
Figure 6.13 Most Active Players: Distribution by Number of Funding Instances and Amount Raised (USD Million)
Figure 6.14 Funding and Investments: Regional Distribution by Amount Invested (USD Million)
Figure 7.1 Clinical Trial Analysis: Scope and Methodology
Figure 7.2 Clinical Trial Analysis: Distribution by Trial Status
Figure 7.3 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, 2000-2020 (Till November)
Figure 7.4 Clinical Trial Analysis: Distribution by Trial Phase
Figure 7.5 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
Figure 7.6 Clinical Trial Analysis: Geographical Distribution by Trial Registration Year and Trial Recruitment Status
Figure 7.7 Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population
Figure 7.8 Clinical Trial Analysis: Distribution by Study Design
Figure 7.9 Clinical Trial Analysis: Distribution by Sponsor / Collaborator
Figure 7.10 Most Active Players: Distribution by Number of Registered Trials
Figure 7.11 Clinical Trial Analysis: Emerging Focus Area
Figure 7.12 Clinical Trial Analysis: Distribution by Trial Phase and Target Disease Indication
Figure 7.13 Clinical Trial Analysis: Geographical Distribution by Number of Clinical Trials
Figure 7.14 Clinical Trial Analysis: Geographical Distribution by Patients Enrolled
Figure 8.1 KOL Analysis: Distribution by Type of Organization (KOL Affiliation)
Figure 8.2 KOL Analysis: Distribution by Location of Organization (KOL Affiliation)
Figure 8.3 KOL Analysis: Leading Organizations (KOL Affiliation)
Figure 8.4 KOL Analysis: Geographical Distribution of KOLs in North America
Figure 8.5 KOL Analysis: Geographical Distribution of KOLs in Europe
Figure 8.6 KOL Analysis: Geographical Distribution of KOLs in Asia-Pacific and Latin America
Figure 8.7 KOL Analysis: Dot-Plot of KOLs
Figure 8.8 KOL Analysis: Most Prominent KOLs
Figure 8.9 KOL Benchmarking: Roots Analysis’ Assessment versus Third Party (ResearchGate Score)
Figure 9.1 Global Immunocytokines Market, 2021-2030 (USD Million)
Figure 9.2 Global Immunocytokines Market, 2021 and 2030: Distribution by Target Disease Indication (USD Million)
Figure 9.3 Immunocytokines Market for Cervical Cancer, 2021-2030 (USD Million)
Figure 9.4 Immunocytokines Market for Cholangiocarcinoma, 2021-2030 (USD Million)
Figure 9.5 Immunocytokines Market for Esophageal Cancer, 2021-2030 (USD Million)
Figure 9.6 Immunocytokines Market for Gallbladder Cancer, 2021-2030 (USD Million)
Figure 9.7 Immunocytokines Market for Head and Neck Cancer, 2021-2030 (USD Million)
Figure 9.8 Immunocytokines Market for Melanoma, 2021-2030 (USD Million)
Figure 9.9 Immunocytokines Market for Non-small Cell Lung Cancer, 2021-2030 (USD Million)
Figure 9.10 Immunocytokines Market for Rheumatoid Arthritis, 2021-2030 (USD Million)
Figure 9.11 Immunocytokines Market for Soft Tissue Sarcoma, 2021-2030 (USD Million)
Figure 9.12 Global Immunocytokines Market, 2021 and 2030: Distribution by Route of Administration (USD Million)
Figure 9.13 Immunocytokines Market for Products Requiring Intravenous Administration, 2021-2030 (USD Million)
Figure 9.14 Immunocytokines Market for Products Requiring Intratumoral Administration, 2021-2030 (USD Million)
Figure 9.15 Immunocytokines Market for Products Requiring Subcutaneous Administration, 2021-2030 (USD Million)
Figure 9.16 Global Immunocytokines Market, 2021 and 2030: Distribution by Geography (USD Million)
Figure 9.17 Immunocytokines Market in the US, 2021-2030 (USD Million)
Figure 9.18 Immunocytokines Market in Canada, 2021-2030 (USD Million)
Figure 9.19 Immunocytokines Market in Germany, 2021-2030 (USD Million)
Figure 9.20 Immunocytokines Market in the UK, 2021-2030 (USD Million)
Figure 9.21 Immunocytokines Market in France, 2021-2030 (USD Million)
Figure 9.22 Immunocytokines Market in Italy, 2021-2030 (USD Million)
Figure 9.23 Immunocytokines Market in Spain, 2021-2030 (USD Million)
Figure 9.24 Immunocytokines Market in China, 2021-2030 (USD Million)
Figure 9.25 Immunocytokines Market in Japan, 2021-2030 (USD Million)
Figure 9.26 Immunocytokines Market in South Korea, 2021-2030 (USD Million)
Figure 9.27 Immunocytokines Market in Australia, 2021-2030 (USD Million)
Figure 9.28 Immunocytokines Market in Brazil, 2021-2030 (USD Million)
Figure 9.29 Immunocytokines Market in Argentina, 2021-2030 (USD Million)
Figure 9.30 Immunocytokines Market in Turkey, 2021-2030 (USD Million)
Figure 9.31 Immunocytokines Market in Israel, 2021-2030 (USD Million)
Figure 9.32 Daromun: Target Patient Population
Figure 9.33 Daromun Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 9.34 F8IL10: Target Patient Population
Figure 9.35 F8IL10 Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 9.36 hu14.18-IL2: Target Patient Population
Figure 9.37 hu14.18-IL2 Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 9.38 L19IL2: Target Patient Population
Figure 9.39 L19IL2 Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 9.40 L19TNF: Target Patient Population
Figure 9.41 L19TNF Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 9.42 M7824: Target Patient Population
Figure 9.43 M7824 Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 9.44 RO6874281: Target Patient Population
Figure 9.45 RO6874281 Sales Forecast (Till 2030): Base Scenario (USD Million)
Table 3.1 Types of Cytokines and Their Functions
Table 4.1 Immunocytokines: Development Pipeline
Table 4.2 Immunocytokines: List of Therapy Developers
Table 5.1 Genopharm: Company Snapshot
Table 5.2 Drug Profile: GNP101
Table 5.3 Drug Profile: GNP201
Table 5.4 Drug Profile: GNP301
Table 5.5 Genopharm: Recent Developments and Future Outlook
Table 5.6 ImmunGene: Company Snapshot
Table 5.7 Drug Profile: IGN001
Table 5.8 Drug Profile: IGN003
Table 5.9 Drug Profile: IGN004
Table 5.10 Drug Profile: IGN005
Table 5.11 Drug Profile: IGN006
Table 5.12 ImmunGene: Recent Developments and Future Outlook
Table 5.13 Kanaph Therapeutics: Company Snapshot
Table 5.14 Drug Profile: KNP-101
Table 5.15 Drug Profile: KNP-102
Table 5.16 Drug Profile: Cytokine X-Anti-Target A
Table 5.17 Drug Profile: Cytokine X-Anti-Target B
Table 5.18 Kanaph Therapeutics: Recent Developments and Future Outlook
Table 5.19 Merck KGaA: Company Snapshot
Table 5.20 Drug Profile: EMD 521873
Table 5.21 Drug Profile: M7824
Table 5.22 Drug Profile: M9241
Table 5.23 Merck KGaA: Recent Developments and Future Outlook
Table 5.24 Philogen: Company Snapshot
Table 5.25 Drug Profile: Daromun
Table 5.26 Drug Profile: F8IL10
Table 5.27 Drug Profile: F16IL2
Table 5.28 Drug Profile: IL12-L19L19
Table 5.29 Drug Profile: L19IL2
Table 5.30 Drug Profile: L19TNF
Table 5.31 Philogen: Recent Developments and Future Outlook
Table 6.1 Immunocytokines: List of Partnerships and Collaborations, 2016-2020 (Till October)
Table 6.2 Immunocytokines: List of Funding and Investments, 2016-2020 (Till October)
Table 8.1 Immunocytokines: List of Principal Investigators
Table 8.2 KOL Profile: A (Maastricht University)
Table 8.3 KOL Profile: B (CLCC Léon Bérard)
Table 8.4 KOL Profile: C (Eberhard Karls University)
Table 8.5 KOL Profile: D (Istituto Clinico Humanitas)
Table 8.6 KOL Profile: E (Washington University in St. Louis)
Table 10.1 Provenance Biopharmaceuticals: Company Snapshot
Table 10.2 Glycotope: Company Snapshot
Table 12.1 Immunocytokines: Distribution by Phase of Development
Table 12.2 Immunocytokines: Distribution by Type of Therapy
Table 12.3 Immunocytokines: Distribution by Type of Cytokine Used
Table 12.4 Immunocytokines: Distribution by Type of Antibody Used
Table 12.5 Immunocytokines: Distribution by Target Disease Indication(s)
Table 12.6 Immunocytokines: Distribution by Route of Administration
Table 12.7 Immunocytokines: Distribution of Developers by Year of Establishment
Table 12.8 Immunocytokines: Distribution of Developers by Company Size and Geographical Location
Table 12.9 Leading Developers: Distribution by Number of Therapies
Table 12.10 Partnerships and Collaborations: Cumulative Year-wise Trend, 2016-2020 (Till October)
Table 12.11 Partnerships and Collaborations: Distribution by Type of Partnership
Table 12.12 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 12.13 Partnerships and Collaborations: Distribution by Year and Type of Partner
Table 12.14 Most Active Players: Distribution by Number of Partnerships
Table 12.15 Partnerships and Collaborations: Regional Distribution
Table 12.16 Funding and Investments: Cumulative Year-wise Trend, 2016-2020 (Till October)
Table 12.17 Funding and Investments: Distribution of Amount Invested by Year and Number of Instances, 2016-2020 (USD Million)
Table 12.18 Funding and Investments: Distribution of Instances by Type of Funding
Table 12.19 Funding and Investments: Distribution by Year and Type of Funding, 2016-2020 (Till October)
Table 12.20 Funding and Investments: Distribution of Instances by Total Amount Invested and Type of Funding (USD Million)
Table 12.21 Most Active Players: Distribution by Number of Funding Instances and Amount Raised (USD Million)
Table 12.22 Clinical Trial Analysis: Distribution by Trial Status
Table 12.23 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, 2000-2020 (Till November)
Table 12.24 Clinical Trial Analysis: Distribution by Trial Phase
Table 12.25 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
Table 12.26 Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population
Table 12.27 Clinical Trial Analysis: Distribution by Study Design
Table 12.28 Leading Trial Sponsors: Distribution by Number of Registered Trials
Table 12.29 Most Active Players: Distribution by Number of Registered Trials
Table 12.30 Clinical Trial Analysis: Geographical Distribution by Number of Clinical Trials
Table 12.31 KOL Analysis: Distribution by Type of Organization (KOL Affiliation)
Table 12.32 KOL Analysis: Distribution by Location of Organization (KOL Affiliation)
Table 12.33 KOL Analysis: Leading Organizations (KOL Affiliation)
Table 12.34 KOL Benchmarking: Most Prominent KOLs
Table 12.35 KOL Analysis: Roots Analysis’ Assessment versus Third Party (ResearchGate Score)
Table 12.36 Global Immunocytokines Market, Conservative, Base, and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.37 Global Immunocytokines Market, 2021 and 2030: Distribution by Target Disease Indication (USD Million)
Table 12.38 Immunocytokines Market for Cervical Cancer, Conservative, Base, and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.39 Immunocytokines Market for Cholangiocarcinoma, Conservative, Base, and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.40 Immunocytokines Market for Esophageal Cancer, Conservative, Base, and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.41 Immunocytokines Market for Gallbladder Cancer, Conservative, Base, and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.42 Immunocytokines Market for Head and Neck Cancer, Conservative, Base, and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.43 Immunocytokines Market for Melanoma, Conservative, Base, and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.44 Immunocytokines Market for Non-small Cell Lung Cancer, Conservative, Base, and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.45 Immunocytokines Market for Rheumatoid Arthritis, Conservative, Base, and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.46 Immunocytokines Market for Soft Tissue Sarcoma, Conservative, Base, and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.47 Global Immunocytokines Market, 2021 and 2030: Distribution by Route of Administration (USD Million)
Table 12.48 Immunocytokines Market for Products Requiring Intravenous Administration, Conservative, Base, and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.49 Immunocytokines Market for Product Requiring Intratumoral Administration, Conservative, Base, and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.50 Immunocytokines Market for Products Requiring Subcutaneous Administration, Conservative, Base, and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.51 Global Immunocytokines Market, 2021 and 2030: Distribution by Geography (USD Million)
Table 12.52 Immunocytokines Market in the US, Conservative, Base, and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.53 Immunocytokines Market in Canada, Conservative, Base, and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.54 Immunocytokines Market in Germany, Conservative, Base, and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.55 Immunocytokines Market in the UK, Conservative, Base, and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.56 Immunocytokines Market in France, Conservative, Base, and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.57 Immunocytokines Market in Italy, Conservative, Base, and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.58 Immunocytokines Market in Spain, Conservative, Base, and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.59 Immunocytokines Market in China, Conservative, Base, and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.60 Immunocytokines Market in Japan, Conservative, Base, and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.61 Immunocytokines Market in South Korea, Conservative, Base, and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.62 Immunocytokines Market in Australia, Conservative, Base, and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.63 Immunocytokines Market in Brazil, Conservative, Base, and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.64 Immunocytokines Market in Argentina, Conservative, Base, and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.65 Immunocytokines Market in Turkey, Conservative, Base, and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.66 Immunocytokines Market in Israel, Conservative, Base, and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.67 Daromun Sales Forecast (Till 2030): Conservative, Base, and Optimistic Scenarios, (USD Million)
Table 12.68 F8IL10 Sales Forecast (Till 2030): Conservative, Base, and Optimistic Scenarios, (USD Million)
Table 12.69 hu14.18-IL2 Sales Forecast (Till 2030): Conservative, Base, and Optimistic Scenarios, (USD Million)
Table 12.70 L19IL2 Sales Forecast (Till 2030): Conservative, Base, and Optimistic Scenarios, (USD Million)
Table 12.71 L19TNF Sales Forecast (Till 2030): Conservative, Base, and Optimistic Scenarios, (USD Million)
Table 12.72 M7824 Sales Forecast (Till 2030): Conservative, Base, and Optimistic Scenarios, (USD Million)
Table 12.73 RO6874281 Sales Forecast (Till 2030): Conservative, Base, and Optimistic Scenarios, (USD Million)
The following companies and organizations have been mentioned in the report.
Source 1: www.who.int/cancer/resources/keyfacts/en/
Source 2: www.researchgate.net/publication/303155524_Harnessing_the_immune_system_to_improve_cancer_therapy/figures?lo=1